Environmentally harmful medical spray propellants are replaced with recycled CO2 through innovation.

Purpose and goal

Our innovative technology, which replaces environmentally harmful propellants with captured, inexpensive, and non-hazardous CO2 in spray products, dramatically lowers the global warming potential while significantly reducing production costs for products such as asthma and COPD inhalers. CO2 is an approved pharmacopeia-classified gas, but our technology also works in other market segments for spray products. Our focus on reusable containers ushers in a new era of environmental responsibility within the aerosol and parts of the pharmaceutical industry.

Expected effects and result

The project is a feasibility study that will define challenges in industrialization, including aspects of product design and detailing what is needed for a pilot facility locally in Karlstad, as well as the steps and financials to scale up the technology. We will also conduct a market size assessment for our innovation within the medical field, evaluate reasonable volumes within 5 years from the start of production, and determine the marketing efforts required to achieve them.

Planned approach and implementation

The project aims to establish the prerequisites needed for the various phases of upcoming industrialization; technically, temporally, and economically. Our work packages include Pilot Plant, Demonstrator Units, Market, IP Rights, Circular Structures, Industry Dialogue with the Swedish Medical Products Agency, Scaling Up Production, and Report Compilation. The work packages do not have a chronological order but will be developed in parallel.